New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:12 EDTAZN, FRX, IRWDIronwood reports Q4 LINZESS net product sales $51M, as reported by Forest
Ironwood (IRWD) says LINZESS net product sales, as reported by Forest Laboratories (FRX) were $51M in Q4, an increase of approximately 48% quarter over quarter, and $118.8M for the year ended December 31, 2013. More than 220,000 LINZESS prescriptions were filled in Q4, resulting in more than 24% growth in total prescriptions quarter over quarter, and over 580,000 LINZESS prescriptions were filled in 2013, according to IMS Health. In 2013, more than 50,000 healthcare practitioners prescribed LINZESS, including approximately 90% of high prescribing gastroenterologists and approximately 70% of other high prescribing healthcare practitioners, primarily primary care physicians. Physician prescribing continues to increase month over month. Almirall, S.A., Ironwood’s European partner, continues to launch CONSTELLA in Europe. CONSTELLA is currently available to adult IBS-C patients in nine countries in Europe, including the United Kingdom and Germany. Ironwood and AstraZeneca (AZN) continue to enroll patients in a Phase III clinical trial of linaclotide in adult patients with IBS-C in China. The trial is expected to be completed in the first half of 2015. Astellas Pharma Inc. has completed enrollment in a Phase II double-blind, placebo-controlled, dose-ranging clinical trial of linaclotide in adult patients with IBS-C in Japan.
News For IRWD;FRX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
14:54 EDTAZNAstraZeneca to hold a conference call
Chief Medical Officer Sean Bohen discusses key potential medicines within the late-stage pipeline and provides further details on progress made in 2015 and anticipated newsflow in 2016 on a conference call to be held on December 2 at 11 am. Webcast Link
11:51 EDTAZNAstraZeneca upgraded two notches to Overweight at Morgan Stanley
Subscribe for More Information
11:38 EDTAZNAstraZeneca upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
07:46 EDTAZNFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
November 30, 2015
16:09 EDTIRWDIronwood, Astellas say Phase 3 linaclotide trial in Japan met primary endpoints
Astellas Pharma (ALPMY) and Ironwood Pharmaceuticals (IRWD) announced that the Phase 3 clinical trial of linaclotide conducted in Japan in adults with irritable bowel syndrome with constipation met its primary endpoints. Astellas expects to submit a new drug application to the Ministry of Health, Labor and Welfare in Japan in 2016, the company noted. Top-line data from the trial indicate linaclotide-treated patients showed "statistically significant" improvement compared to placebo-treated patients for both of the two co-primary endpoints. Regarding the first primary endpoint, 34% of linaclotide-treated patients were so-called Global Assessment of Relief of IBS Symptoms Responders, compared to 18% of placebo-treated patients. Regarding the second primary endpoint, 35% of linaclotide-treated patients were Complete Spontaneous Bowel Movement Overall Responders, compared to 19% of placebo-treated patients. Additionally, improvements were achieved in pre-specified secondary endpoints in the trial covering abdominal and constipation symptoms, including bloating and abdominal pain. Diarrhea rates in the trial were 9.6% for linaclotide versus 0.4% for placebo.
08:02 EDTIRWDIronwood says Phase II Linaclotide trial data 'positive'
Subscribe for More Information
November 23, 2015
07:59 EDTAZNPerrigo acquires Entocort from AstraZeneca for $380M
Subscribe for More Information
06:00 EDTAZNAstraZeneca sells U.S. Entocort drug rights to Perrigo for $380M
Subscribe for More Information
November 20, 2015
07:31 EDTAZNLabcyte, AstraZeneca partner to develop acoustic liquid handling system
Labcyte announced a partnership with AstraZeneca to develop a state-of-the-art automated pharmaceutical compound management system based on its revolutionary Echo acoustic liquid handling technology. The new system, which will employ storage tubes compatible with acoustic liquid handling, will be deployed at the AstraZeneca MRC UK Centre for Lead Discovery in Cambridge.
06:09 EDTAZNSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
16:43 EDTAZNBIND Therapeutics gets $4M milestone payment from AstraZeneca
Subscribe for More Information
08:11 EDTAZNIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:02 EDTAZNBIND says AstraZeneca initiates patient dosing in AZD2811 Phase 1 trial
Subscribe for More Information
07:26 EDTAZNZS Pharma downgraded to Neutral from Buy at Citi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use